chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 26.0
Sex: U
Vaccine: COVID19
Symptoms: Dehydration, Fatigue, Pain
Clinical narrative: Extreme body aches; Extreme fatigue; mild dehydration; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old patient of unknown gender received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 23Mar2021 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included emtricitabine, tenofovir alafenamide fumarate, bictegravir sodium (BIKTARVY); taken for unknown indication on an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the right arm on 01Mar2021 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient had not been diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021, after second dose, the patient experienced extreme body aches, extreme fatigue and mild dehydration; all symptoms experienced for a full day and were gone the following day after that. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event extreme body aches, extreme fatigue and mild dehydration were recovered on 25Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lethargy, Vaccination site erythema, Vaccination site pain, Vaccination site pruritus
Clinical narrative: headache; lithargy; sore at shot site; redness at shot site; itch at shot site; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 08Apr2021 at 13:00 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient did receive unspecified medication within two weeks of vaccination. The patient previously received DIOVAN for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208) via an unspecified route of administration in the left arm on 18Mar2021 at 13:00 (at the age of 68-years-old) as a single dose for COVID-19 immunisation and also received LISINOPRIL for unknown indication and experienced mild cough. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021, the patient experienced sore, redness and itch at shot site, plus on 12Apr2021, after 4 days, the patient experienced headache and lithargy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events sore at shot site, redness at shot site, itch at shot site, headache and lithargy were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Rash erythematous, Rash pruritic, Swelling
Clinical narrative: Severe Rash started on arm, face, penis and scrotum; Redness; Swelled; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL9262) via an unspecified route of administration in the right arm on 03Feb2021(at the age of 34-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma and seasonal allergy. Concomitant medications included fexofenadine hydrochloride (ALLEGRA ALLERGY) received within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number:EL1284 ) via an unspecified route of administration in the right arm on 14Jan2021(at the age of 34-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Mar2021, the patient experienced severe rash which started on arm, face, penis and scrotum, swelled, itching and redness. The patient stated prednisone did not help and rash spread across most of body over 2 and a half weeks and finally has stopped spreading. Therapeutic measures were taken as a result of the events which included treatment with prednisone. The clinical outcome of severe rash started on arm, face, penis and scrotum, swelled and itch and redness were resolving.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Abnormal dreams, Fatigue
Clinical narrative: Dreams have been very star game and vivid; heavy fatigue; This is a spontaneous report from a contactable other healthcare professional. A 43-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the right arm on 20Mar2021 at 14:15 (at the age of 43-years-old) and the patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0150) via an unspecified route of administration in the right arm on 11Apr2021 at 15:00 (at the age of 43-years-old) as a dose for COVID-19 immunisation. Medical history included shellfish allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021, the patient had dreams that had been very star game and vivid after both shots and also, heavy fatigue after both shots. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events dreams had been very star game and vivid and heavy fatigue were unknown at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Fatigue, Pain, Pyrexia
Clinical narrative: Fever; chills; fatigue; weakness; body aches; This is a spontaneous report from a contactable consumer, the patient. A 63-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 11Apr2021 at 15:45 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, blood pressure high and COVID-19 on an unknown date in Jan2021. The patient was allergic to penicillin. Concomitant medications included metformin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), amlodipine besilate, olmesartan medoxomil (AZOR), metoprolol (MANUFACTURER UNKNOWN) and hydralazine (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 01:00 the patient experienced fever, chills, fatigue, weakness/ body aches. Therapeutic measures were not taken as a result of the adverse event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events fever, chills, fatigue, weakness and body aches were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral, Oral discomfort, Throat irritation, Tongue discomfort
Clinical narrative: 5 hours after injection I had facial andoral numbness; oral numbness; throat irritation/throat hadburning sensation.; Following morning ate a protein barand mouth, tongue and throat hadburning sensation.; tongue burning; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0151) via an unspecified route of administration in the left arm on 11Apr2021 at 12:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Concomitant medications included cetirizine hydrochloride (ZYRTEC), vitamin d nos (VITAMIN D), ascorbic acid (VITAMIN C), and calcium (MANUFACTURER UNKNOWN) all from an unknown date for an unspecified indication. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 17:00, the patient experienced facial and oral numbness and throat irritation. Following morning she ate a protein bar and mouth, tongue and throat had burning sensation. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with BENADRYL. The clinical outcome of the events facial and oral numbness and throat irritation, and mouth, tongue and throat had burning sensation was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Body temperature, Peripheral coldness, Pyrexia
Clinical narrative: Loss of taste; Feet felt like ice cubes; Fever of slightly over 100 degrees; This is a spontaneous report from a non-contactable consumer, the patient. A 68-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration on an unknown date (at the age of 68-year-old) as a single dose for COVID-19 immunisation. Medical history included liver disease. The patient had no known allergies to medications, food, or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 10Apr2021 at 13:00, the patient experienced loss of taste, feet felt like ice cubes and fever (body temperature was slightly over 100 degrees) after second dose. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events loss of taste, feet felt like ice cubes and fever of slightly over 100 degrees were recovered on an unknown date in Apr2021   No follow-up attempts are possible. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Cough, Fatigue, Pain, Pyrexia
Clinical narrative: Pain in area; Fever; Fatigue; Chills; Dry cough; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 09Apr2021 at 09:30 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included hydroxyzine (MANUFACTURER UNKNOWN), sertraline (MANUFACTURER UNKNOWN), multivitamins (MANUFACTURER UNKNOWN) and norethisterone acetate; ethinylestradiol; ferrous fumarate (BLISOVI FE); all were taken for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 20Mar2021(at the age of 23-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 04:00, the patient experienced pain in area, fever, fatigue, chills and dry cough. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the events pain in area, fever, fatigue, chills and dry cough were recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia
Clinical narrative: Next day had fever of 101.7; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8737) via an unspecified route of administration in the arm left on 06Apr2021 at 15:00 (at the age of 68-Year-Old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications included ubidecarenone (Q10), fluorescein sodium (FLORES), dutasteride (AVODART), rosuvastatin calcium (CRESTOR) and omeprazole (MANUFACTURER UNKNOWN); all from an unknown for unspecified indication. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: EN6204) via an unspecified route of administration in the left arm on 03Apr2021 at 15:00 (at the age of 67-Year-Old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 07Apr2021 at 10:00 (next day), the patient experienced fever of 101.7. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. On 07Apr2021, the patient underwent body temperature test and the result was 101.7 (Unspecified units). The clinical outcome of the event fever of 101.7 was recovered on unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Arthritis, Condition aggravated, Confusional state, Mechanical urticaria, Myalgia
Clinical narrative: Brain fog; sharp muscle pain; paresthesia in arm and leg; random inflammation of joints; dermatographia. Exacerbation of past inflammatory symptoms; sharp muscle pain; paresthesia in arm and leg;; random inflammation of joints; dermatographia.; Exacerbation of pastinflammatory symptoms; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 19Mar2021 at 13:30(at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic urticaria and allergy to kidney shaped beans, latex. Concomitant medications included oral contraceptive pills (MANUFACTURER UNKNOWN), metformin hydrochloride (MANUFACTURER UNKNOWN) and spironolactone (MANUFACTURER UNKNOWN); all for unspecified indication and unknown start date. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 30Mar2021, the patient experienced brain fog, sharp muscle pain, paresthesia in arm and leg, random inflammation of joints, dermatographia, exacerbation of past inflammatory symptoms. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. On 03Apr2021, the patient underwent nasal swab test and the result was negative. The clinical outcome of the event brain fog, sharp muscle pain, paresthesia in arm and leg, random inflammation of joints, dermatographia and exacerbation of past inflammatory symptoms was not recovered, at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia, SARS-CoV-2 test
Clinical narrative: Brain fog; sharp muscle pain; paresthesia in arm and leg; random inflammation of joints; dermatographia. Exacerbation of past inflammatory symptoms; sharp muscle pain; paresthesia in arm and leg;; random inflammation of joints; dermatographia.; Exacerbation of pastinflammatory symptoms; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 19Mar2021 at 13:30(at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic urticaria and allergy to kidney shaped beans, latex. Concomitant medications included oral contraceptive pills (MANUFACTURER UNKNOWN), metformin hydrochloride (MANUFACTURER UNKNOWN) and spironolactone (MANUFACTURER UNKNOWN); all for unspecified indication and unknown start date. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 30Mar2021, the patient experienced brain fog, sharp muscle pain, paresthesia in arm and leg, random inflammation of joints, dermatographia, exacerbation of past inflammatory symptoms. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. On 03Apr2021, the patient underwent nasal swab test and the result was negative. The clinical outcome of the event brain fog, sharp muscle pain, paresthesia in arm and leg, random inflammation of joints, dermatographia and exacerbation of past inflammatory symptoms was not recovered, at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: Blurry vision; This is a spontaneous report from a non-contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10Apr2021 at 13:30 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine sodium (SYNTHROID) from an unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 12Apr2021, the patient experienced blurry vision. Therapeutic measures were not taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event blurry vision was not resolved at the time of this report.  No follow-up attempts are possible; Information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Muscle tightness, Myalgia
Clinical narrative: Arm muscle soreness; Some chills; Muscle tension; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 11Apr2021(at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and crustaceans/shellfish allergy. Concomitant medications included Multi-vitamins (MANUFACTURER UNKNOWN, ascorbic acid (VIT C), colecalciferol (VIT D3), fish oil (MANUFACTURER UNKNOWN), ascorbic acid, vaccinium spp. (CRANBERRY) and mexiletine hydrochloride (MELATE); all for unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021, the patient experienced arm muscle soreness, some chills and muscle tension. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events arm muscle soreness, some chills and muscle tension were unknown at the time of this report.  No follow up attempts are needed. No further information is expected.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Herpes zoster, Neuralgia, Rash, Vaccination site rash
Clinical narrative: Shingles; Developed rash at injection site within 18 hours; Developed rash at injection site within 18 hours. Spread to upper left arm down to palm within 3 days; some SOB/continued SOB; shooting nerve pains in L arm; This is a spontaneous report from a contactable consumer or other non hcp (patient).    A 75-years-old male patient received second dose of BNT162b2 (BNT162B2, Solution for injection, Batch/Lot number: ER8729), via an unspecified route of administration in left arm on 08Apr2021 at 12:00 (age at vaccination 75 years) as single dose for COVID-19 immunization. The patient's medical history included post-traumatic stress disorder, hypokalaemia, arrhythmia, diabetes, diffuse idiopathic skeletal hyperostosis, drug allergy to penicillin and flu vaccine, all from an unknown date and unknown if ongoing. The patient's concomitant medications included fluoxetine HCL, (POTASSIUM CHLORIDE) and atorvastatin calcium (ATORVASTIN) all taken for an unspecified indications, start and stop dates were not reported. The patient previously received first dose of BNT162b2 (BNT162B2, Solution for injection, Batch/Lot number: EN6204), via an unspecified route of administration in left arm on 18Mar2021 14:00 as single dose for COVID-19 immunisation. The patient experienced shingles, developed rash at injection site within 18 hours developed rash at injection site within 18 hours, spread to upper left arm down to palm within 3 days, some sob/continued sob, shooting nerve pains in L arm on 09Apr2021 at 10:00. The patient stated that, developed rash at injection site within 18 hours, spread to upper left arm down to palm within 3 days with some SOB, shooting nerve pains in L arm. Visited ER on 11Apr2021, dx as shingles, given oral steroid and anti-viral oral med. Visited PCP on 14Apr2021 due to increase of coverage and continued SOB. Steroid injection given, increased dosage of oral steroid. PCP probable dx as Shingles, collected culture. Therapeutic measures taken as a result of the events included emergency room visit on 11Apr2021 and physician office visit on 14Apr2021. Treatment included oral steroid, steroid injection and oral anti-viral medications. The outcome of the events was not recovered at the time of this report.  Follow-up (18Aug2021): Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Neck pain
Clinical narrative: Stomach pain; Neck pain; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Ew0162), via an unspecified route of administration in the left arm on 12Apr2021 at 14:45 (at the age of 44-years-old) as single dose for COVID-19 immunisation. The patient had not reported any other health issues. The patient had no known allergies to medications, food or other products. Concomitant medication included paracetamol (TYLENOL) from an unknown date for unknown indication. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. On 12Apr021 at 15:00, the patient experienced stomach pain and neck pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of stomach pain and neck pain were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Contusion, Lymph node pain, Lymphadenopathy, Pyrexia
Clinical narrative: Fever; Axillary lymphadenopathy with pain and bruising; Axillary lymphadenopathy with pain and bruising; Axillary lymphadenopathy with pain and bruising; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 10Apr2021 at 15:00 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. Concomitant medications included hydrochlorothiazide (MANUFACTURER UNKNOWN), propranolol hydrochloride (PROPRANOLOL) and valsartan (MANUFACTURER UNKNOWN), all used for unknown indication from unspecified dates, unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021 at 14:00 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 08:00, the patient experienced fever and axillary lymphadenopathy with pain and bruising. No therapeutic measures were taken as a result of these events. These events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events fever and axillary lymphadenopathy with pain and bruising was recovering at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Rhinorrhoea
Clinical narrative: Chills; Headache; Stuffy/runny nose; Tired; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 05Apr2021 at 12:30 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood obese. The patient did not receive any concomitant medications. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021, the patient experienced chills, headache, stuffy/runny nose and tired. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of these events which included treatment with TYLENOL and ADVIL from an unknown date in 2021. The clinical outcome of the events chills, headache, stuffy/runny nose and tired was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Gait inability
Clinical narrative: Very weak; Unable to walk without assistance.; This is a spontaneous report from a contactable nurse, the patient. A 65-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08Apr2021 at 08:30 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included Congestive Heart Failure (CHF), Rheumatoid Arthritis (RA), fibromyalgia and Chronic Obstructive Pulmonary Disease (COPD). The patient was allergic to latex and nickel. Concomitant medications included multivitamins (MANUFACTURER UNKNOWN), taken for an unspecified indication from an unknown date. The patient previously received the first dose BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 11Mar2021 at 08:30 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 08:00, two days after the second vaccine, the patient felt very weak and was unable to walk without assistance. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events very weak and unable to walk were resolved on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache
Clinical narrative: severe fatigue; Chills; headache; This is a spontaneous report from a non-contactable consumer, the patient. A 65-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8727) via an unspecified route of administration in the arm left on 09Apr2021 at 12:00 (at the age of 65-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN 6307) via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 65-years-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 10Apr2021 at 12:00 almost exactly 24 hours after receiving the injection, the patient experienced severe fatigue, chills, and headache, but no fever. She took acetaminophen and went to bed. Symptoms continued for at least 12 hours, and were gone by the next morning. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event severe fatigue, chills and headache were recovered on 11Apr2021.    No follow-up attempts are possible. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chills, Fatigue, Headache, Pain
Clinical narrative: Chest tightness within 1 hour of shot that dissipated within 30 minutes from onset; Body aches that lingered for four days; Headache; Bouts of chills; Tiredness; This is a spontaneous report from a non-contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) in the left arm on 03Apr2021 at 10:00 (at the age of 44-years-old) as a dose for COVID-19 immunisation. Medical history included high blood pressure high and COVID-19. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 10:30, the patient experienced chest tightness within 1 hour of shot that dissipated within 30 minutes from the onset but was followed by body aches that lingered for four days and a headache that still lingered a week later at the time of reporting along with bouts of chills and tiredness. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event chest tightness was recovered on 03Apr2021 at 11:00, after a duration of 30 minutes. The clinical outcome of the events body aches, headache, chills and tiredness was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Confusional state, Feeling abnormal
Clinical narrative: Severe confusion; Brain fog starting on april 11th at 11am (upon waking); This is a spontaneous report from a contactable consumer, the patient. A 20-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10Apr2021 at 09:30 (at the age of 20-year-old) as a single dose for COVID-19 immunisation. Medical history included depression. The patient did not have allergies to medications, food or other products. The patient received other medications (unspecified) within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Mar2021 at 15:15 (at the age of 20-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed for COVID-19. On 11Apr2021 at 11:00, the patient experienced severe confusion and brain fog upon waking. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe confusion and brain fog upon waking was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Pruritus, Skin discolouration, Vaccination site erythema
Clinical narrative: purplish hue; slightly itchy; red mark appeared below inject site; "red mark appeared below inject site and it hot to touch"; Red bump at injection site; muscle soreness-arm, neck and leg on right side; tiredness; 1.5 below inject site hurt to touch/ red mark increased in size, still hotter than other skin temperature, and hurts to touch; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 08Apr2021 at 14:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes and mild strawberry allergy. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and vitamin d nos (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 18Mar2021 at 14:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 09Apr2021, day after shot, the patient experienced red bump at injection site, muscle soreness - arm, neck and leg on right side, tiredness, and 1.5" below inject site hurt to touch. On 10Apr2021, day two, the patient experienced same as above but red mark appeared below inject site and it hot to touch. Day three, the patient experienced muscle soreness and tiredness ebbs, red mark increased in size, still hotter than other skin temperature, and hurt to touch. On 12Apr2021, day four, the patient experienced same but the mark had a purplish hue and slightly itchy. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event red bump at injection site, muscle soreness-arm, neck and leg on right side, tiredness, 1.5 below inject site hurt to touch, "red mark appeared below inject site and hot to touch"/ red mark increased in size, still hotter than other skin temperature, and hurts to touch, purplish hue and slightly itchy was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site pain, Vaccination site warmth
Clinical narrative: purplish hue; slightly itchy; red mark appeared below inject site; "red mark appeared below inject site and it hot to touch"; Red bump at injection site; muscle soreness-arm, neck and leg on right side; tiredness; 1.5 below inject site hurt to touch/ red mark increased in size, still hotter than other skin temperature, and hurts to touch; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 08Apr2021 at 14:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes and mild strawberry allergy. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and vitamin d nos (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 18Mar2021 at 14:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 09Apr2021, day after shot, the patient experienced red bump at injection site, muscle soreness - arm, neck and leg on right side, tiredness, and 1.5" below inject site hurt to touch. On 10Apr2021, day two, the patient experienced same as above but red mark appeared below inject site and it hot to touch. Day three, the patient experienced muscle soreness and tiredness ebbs, red mark increased in size, still hotter than other skin temperature, and hurt to touch. On 12Apr2021, day four, the patient experienced same but the mark had a purplish hue and slightly itchy. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event red bump at injection site, muscle soreness-arm, neck and leg on right side, tiredness, 1.5 below inject site hurt to touch, "red mark appeared below inject site and hot to touch"/ red mark increased in size, still hotter than other skin temperature, and hurts to touch, purplish hue and slightly itchy was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Fatigue, Glossodynia, Tongue discomfort, Vaccination site pain
Clinical narrative: Abdominal discomfort; Soreness in left arm (injection site); General fatigue; Tongue tender; Tongue feels like sandpaper; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0150), via an unspecified route of administration in the left arm on 11Apr2021 at 14:00 (at the age of 33-year-old), as a single dose for COVID-19 immunisation. Medical history included gallbladder removal on an unknown date which was not ongoing. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included multivitamins (MANUFACTURER UNKNOWN) and iron (MANUFACTURER UNKNOWN) for an unknown indication and from unknown dates. On 11Apr2021 at 15:00, the patient's tongue felt like sandpaper and tender. On 12Apr2021, the patient experienced soreness in the left arm at the injection site, general fatigue, and abdominal discomfort. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events tongue feels like sandpaper, tongue tender, soreness in left arm (injection site), general fatigue and abdominal discomfort were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Lymph node pain, Lymphadenopathy, Pain, Pyrexia
Clinical narrative: Fever; chills; aches for 24 hrs; swollen lymph nodes under left arm; sore, swollen lymph node under myleft arm for several day; This is a spontaneous report from a non-contactable consumer, the patient. A 50-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 01Apr2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 the patient experienced fever, chills, aches for 24 hours and a sore, swollen lymph node under left arm for several days. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, aches for 24 hours and a sore, swollen lymph node under left arm was recovered on an unspecified date in Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling of eyelid
Clinical narrative: left eyelid swelling around the eyelash line; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08Apr2021 at 11:45 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Patient had no relevant medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 11:00, the patient experienced left eyelid swelling around the eyelash line, causing discomfort in both eye. The patient was not sure if it was an allergic reaction to some new makeup she bought, but she don't know. The patient did not receive any treatment for the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left eyelid swelling around the eyelash line was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.